GT Biopharma announced it made the payment for the license of PainBrake, a non-opioid medication from Accu-Break Pharmaceuticals, which the company plans to develop.

GT Biopharma (OTCQB:OXISD) announced it made the payment for the license of PainBrake, a non-opioid medication from Accu-Break Pharmaceuticals, which the company plans to develop.
As quoted in the press release:

The payment allows GT Biopharma to begin the clinical development process and the filing of a New Drug Application, the final step for a commercial license from the Food and Drug Administration. The company expects to submit an NDA for PainBrake within 18 months.
PainBrake will use a patented technology – and unique shape – that allows tablets to be easily broken into smaller, precise doses, for maximum dose flexibility and accuracy. The top layer contains the pain-killer and is pre-divided by deep scoring during the manufacturing process to provide exact doses.

Click here to read the full press release.

Source: www.accesswire.com

biopharma food and drug administration manufacturing nda new drug application pain Pharmaceutical Investing